BioMarin Awaits Pivotal INZ-701 Trial Results Following $270M Inozyme Acquisition
核心洞察
BioMarin completed its $270 million acquisition of Inozyme Pharma in July 2025, paying $4.00 per share to gain access to the enzyme replacement therapy INZ-701.
The experimental therapy targets ENPP1 Deficiency (搜索), a rare genetic disorder causing dangerous blood vessel and bone calcification, with early data showing 80% infant survival versus 50% historical rates.
Critical Phase 3 ENERGY-3 trial results are expected in early 2026, which could lead to regulatory submission and potential market approval by 2027.
BioMarin Pharmaceutical has completed its strategic $270 million acquisition of Inozyme Pharma, positioning the company for a critical data readout that could validate the investment and expand its rare disease portfolio. The all-cash transaction, finalized on July 1, 2025, brought the late-stage enzyme replacement therapy INZ-701 into BioMarin's pipeline, targeting two rare genetic disorders with significant unmet medical needs.
Strategic Acquisition Details
The acquisition was executed through BioMarin's subsidiary, Incline Merger Sub, Inc., following an initial agreement announced on May 16, 2025. Shareholders received $4.00 per share in cash, with approximately 70% of outstanding shares tendered during the offer period that concluded on June 30, 2025. All remaining shares were automatically converted at the same price upon merger completion. Inozyme's stock has been delisted from the Nasdaq Global Select Market and is no longer publicly traded.
INZ-701: Targeting Rare Genetic Disorders
Central to the acquisition is INZ-701, an enzyme replacement therapy designed to treat ENPP1 Deficiency (搜索) and ABCC6 Deficiency (搜索). ENPP1 Deficiency is a severe genetic condition that leads to dangerous calcification of blood vessels and bone due to an enzyme shortfall. The therapy has demonstrated promising clinical potential in early-stage studies.
Previous Phase 1/2 clinical trial data indicated a favorable safety profile for INZ-701, alongside observed improvements in pyrophosphate levels and biomarkers for bone mineralization. In January 2025, Inozyme reported positive interim results from its ENERGY-1 study and an expanded access program. The U.S. Food and Drug Administration granted INZ-701 Fast Track designation for ABCC6 Deficiency (搜索) in July 2024.
Critical Data Readout Approaching
The first quarter of 2026 represents a significant catalyst for the acquisition's success. BioMarin is preparing to release topline results from its pivotal ENERGY-3 study, a pediatric trial that will form the core of the regulatory submission for INZ-701. Patient recruitment for this decisive study was finalized in January 2025.
Earlier data have generated considerable optimism about the therapy's potential. Results from the ENERGY-1 program and compassionate use cases indicated a dramatically improved survival rate, with 80% of treated infants surviving compared to the historical survival rate of roughly 50% for children with the condition who do not receive the therapy.
Regulatory and Commercial Timeline
Positive outcomes from the ENERGY-3 trial would trigger BioMarin's submission of a Biologics License Application to health authorities. The full integration of Inozyme into BioMarin's operations allows the company to leverage its global development infrastructure for the regulatory process.
A successful data readout sets the stage for potential market approval of INZ-701 by 2027. This timeline would enable BioMarin to solidify its standing in the highly specialized rare disease sector and establish a foundation for sustained growth beyond this specific program. The strategic consolidation positions BioMarin to expand its enzyme replacement therapy portfolio while addressing critical unmet medical needs in rare genetic disorders.